FDA establishes new advisory committee for genetic metabolic disease treatments

The FDA is assembling a new advisory committee to evaluate potential treatments for genetic metabolic diseases, the agency announced Tuesday.

Genetic metabolic diseases are typically rare conditions that disrupt a person’s metabolism, the FDA explained. The new panel will be composed of experts in metabolic genetics,…
Click here to view original post